全球嵌合抗原受体 T (CAR-T) 细胞市场 – 行业趋势和 2029 年预测

市场分析和规模

近年来，嵌合抗原受体 (CAR) T 细胞治疗领域取得了非凡的增长，预计未来几年将继续保持这一势头。研发活动投资的增加、新参与者的进入、产品创新、技术突破、有效的资源配置以及业务竞争对手之间为扩大其区域和客户群而日益激烈的竞争都促进了该行业的增长。

Data Bridge Market Research 分析，嵌合抗原受体 T (CAR-T) 细胞市场在 2021 年为 19.658 亿美元，到 2029 年将飙升至 287.14 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 39.82%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分                               

市场定义

CAR-T therapy is a type of treatment in which a patient's T cells, which are immune cells, are genetically engineered in the lab to kill cancer cells. T cells are collected from a patient's blood. T cells in the lab are given the gene for a specific receptor that binds to a specific protein on the patient's cancer cells. Chimeric antigen receptors are a special kind of receptor (CAR). CAR-T cells are mass-produced in the lab and then injected into the patient. CAR-T therapy is used to treat certain types of blood cancers and is also being studied for use in other cancers.

Chimeric Antigen Receptor T (CAR-T) Cells Market Dynamics

Drivers

• Increasing occurrences of cancer

In the forecast period of 2022-2029, rising levels of investment for the development of advanced and technical solutions and products, an increase in the number of cell therapy clinical studies, and the growth of the pharmaceutical industry will all help to accelerate the growth of the chimeric antigen receptor T (CAR-T) cells market. In the forecast period, increasing use of cells for the treatment of various hematologic and solid tumour types would enhance numerous prospects, resulting in the expansion of the chimeric antigen receptor T (CAR-T) cells market.

• Increasing number of patients

The rise in the frequency of cancer, the increase in the number of patients who have failed to respond to alternative treatments, and the rise in healthcare costs are all predicted to promote the growth of the chimeric antigen receptor (CAR)-T cell therapy market in the forecast period.

• Increasing approvals for Car-T cell therapy products

As people become more aware of this novel way of treating cancer, demand for auto T cell therapy products rises. As a result, leading market players are working on new products, which is driving the industry forward. The US Food and Drug Administration authorized Yescarta, a cell-based gene therapy, in October 2017 to treat adult patients with certain kinds of large B-cell lymphoma. Yescarta's clearance is a breakthrough in the field of CAR-T cell treatments for cancer patients.

• Increasing R&D therapies

By 2028, the global CAR T-cell treatment industry is estimated to reach $15 billion. CAR T-cell therapy providers are likely to benefit from increased attention on research and development medicines for cancers such as lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer. In addition to cancer, researchers are verifying the function of therapy in a variety of other diseases, such as HIV, autoimmune disorders, infections, and others, which will drive the market's growth throughout the forecast period.

Opportunities

In addition, as people become more aware of efficiency, the market for chimeric antigen receptor (CAR)-T cell treatment is expected to develop in the coming years. However, the potential for cytokine release syndrome (CRS) and other neurological disorders as a result of cell therapy could provide further growth prospects for the chimeric antigen receptor (CAR)-T cell therapy industry in the near future.

Restraints/Challenges

In the predictable future, high treatment costs and negative effects associated with CAR T cell use would operate as a market restraint for the expansion of chimeric antigen receptor T (CAR-T) cells.

This chimeric antigen receptor T (CAR-T) cells market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chimeric antigen receptor T (CAR-T) cells market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 impact on Chimeric Antigen Receptor T (CAR-T) Cells Market

The COVID-19 epidemic has caused widespread economic and social disruption. The disease has infiltrated various sectors' value and supply chains, including the market for chimeric antigen receptor (car) t-cell treatment. The authorities implemented lockdowns in several regions. We'll look at both demand and supply to see how the COVID-19 epidemic has affected the global market. To provide a summary, the short- and long-term effects of the COVID-19 pandemic would be investigated. During and after the outbreak, this would aid in the development of business plans for all market participants, including manufacturers, vendors, suppliers, distributors, and end-users.

Recent Development

• In February 2021, After getting FDA permission for commercialization in the United States, Bristol Myers Squibb marketed Breyanzi (lisocabtagene maraleucel). Breyanzi is a cell-based gene therapy used to treat certain kinds of big B-cell lymphoma in adults.
• In July 2020, After getting FDA permission for commercialization in the United States, Kite Pharma, a Gilead Sciences subsidiary, introduced Tecartus. Tecartus (brexucabtagene autoleucel, formerly KTE-X19) is the first and only CAR T-cell therapy licenced for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Global Chimeric Antigen Receptor T (CAR-T) Cells Market Scope

嵌合抗原受体 T (CAR-T) 细胞市场根据目标抗原、应用和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

靶抗原

• CD19
• CD22
• 其他的

应用

• 急性淋巴细胞白血病
• 弥漫性大 B 细胞淋巴瘤
• 其他的

最终用户

• 医院
• 癌症研究中心
• 诊所

嵌合抗原受体 T (CAR-T) 细胞 市场区域分析/见解

对嵌合抗原受体 T（CAR-T）细胞市场进行了分析，并按国家、目标抗原、应用和最终用户提供了市场规模洞察和趋势，如上所述。

嵌合抗原受体 T（CAR-T）细胞市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于癌症发病率高，北美在嵌合抗原受体 T（CAR-T）细胞市场占据主导地位。

由于医疗保健基础设施的完善以及人民的可支配收入的不断增长，预计亚太地区将在 2022 年至 2029 年的预测期内实现最高增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和嵌合抗原受体 T (CAR-T) 细胞市场份额分析

嵌合抗原受体 T (CAR-T) 细胞市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对嵌合抗原受体 T (CAR-T) 细胞市场的关注有关。

嵌合抗原受体 T (CAR-T) 细胞市场的一些主要参与者包括：

• 诺华公司（瑞士）
• 辉瑞公司（美国）
• 吉利德科学公司（美国）
• Autolus Therapeutics（英国）
• 科济生物治疗有限公司（英国）
• Juno Therapeutics, Inc.（美国）
• Sorrento Therapeutics, Inc.（美国）
• 传奇生物科技（美国）
• Calyxt Inc.（法国）
• Mustang Bio（美国）
• bluebird bio, Inc.（美国）
• CELGENE 公司（美国）
• Eureka Therapeutics Inc.（美国）
• Avacta Life Sciences Ltd.（英国）

SKU-52938